DrugDashboards

Escitalopram Oral Solution

Escitalopram Oral · ESCITALOPRAM OXALATE 5 mg/5mL · Solution · Oral · Chartwell Governmental & Specialty RX, LLC.

NDC 68999-0729-24 · 2 TRAY in 1 BOX / 10 CUP in 1 TRAY / 10 mL in 1 CUP · ANDA · View full market →

The short version

Just 2 companies supply this market — thin enough that a single exit would be felt immediately.

The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.

Medicare Part D

No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.

How Part D pricing works →

NADAC price per unit

No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.

Supply fragility

Not scored — fragility is computed for NADAC-priced NDCs.

90-day shortage risk (model v2)

0.1%chance of a new FDA shortage posting for escitalopram oral (other) in the next 90 days

sole-source market

For scale: the typical drug’s chance is about 0.1% — this one is in ordinary territory.

Backtested statistical model over the whole market, not this package alone. Model details →

Regulatory

Application
ANDA090477
TE code
AA
Approval date
Jun 12, 2013
Patents / exclusivity
None on file

Shortage history

No FDA shortage reports for this drug or its presentations.

Recalls (this NDC)

No enforcement reports list this package NDC.

Manufacturers of Escitalopram Oral (Solution)

LabelerStrengthFirst seenLast seen
Chartwell Governmental & Specialty RX, LLC.ESCITALOPRAM OXALATE 5 mg/5mLJul 15, 2026Sep 2, 2026
Chartwell RX, LLCESCITALOPRAM OXALATE 5 mg/5mLJul 15, 2026Sep 2, 2026

Roster from daily NDC Directory diffs — first/last seen dates start July 2026.

Cite this page

DrugDashboards, "Escitalopram Oral Solution — NDC 68999-0729-24," retrieved September 3, 2026, https://drugdashboards.com/drug/68999072924.

Free to cite with attribution — see how the data is put together.